Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future DirectionsKatarzyna Szklener, Sławomir Mańdziuk|Cells|2022Cited by 43
Phase 2 study of retifanlimab (INCMGA00012) in patients (pts) with selected solid tumors (POD1UM-203).Michele Maio, Tibor Csőszi, Jacques Médioni et al.|Journal of Clinical Oncology|2021Cited by 7